Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Links shared publicly online about this topic.

351
total visits

Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.

View full resource at news-medical.net

Tags: Pharma, Forest Laboratories